Insurance data reveals dramatic regional differences in Ozempic and Mounjaro usage, with obesity-heavy states prescribing GLP-1 medications at triple the rate of others.
Original Source:
https://www.foxnews.com/health/america-obesity-crisis-meets-ozempic-boom-data-reveals-glp-1-hot-spots
